How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Swiggy aims to raise a total of ₹11,327.43 crore from this IPO, marking it as the second-largest IPO in India this year after ...

The top gainers on the BSE Sensex pack were IT heavyweights Tata Consultancy Services (TCS), HCL Tech, Infosys, and Tech Mahindra, followed by Adani Ports, Bharti Airtel, Sun Pharma, and M&M. On the ...

India's Mankind Pharma reported a better-than-expected second-quarter profit on Tuesday, driven by strong demand for its drugs to treat long-term illnesses, such as diabetes and cardiovascular ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Indian generic injectables maker Gland Pharma reported a drop in second-quarter profit on Monday, hurt by lower sales in its Europe business and temporary production issues at its French unit Cenexi.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Shares of Sun Pharmaceutical fell 2.64 per cent after the ... based on overall health GDPI in Fiscal 2024, has fixed the ...

Shares of several companies including M&M, Bharti Airtel, Nykaa, and Sun Pharma, among others, will be in the news today on ...